10,188 Shares in REGENXBIO Inc. (NASDAQ:RGNX) Bought by Laurion Capital Management LP

Laurion Capital Management LP bought a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 10,188 shares of the biotechnology company’s stock, valued at approximately $79,000.

A number of other hedge funds have also bought and sold shares of RGNX. GAMMA Investing LLC increased its stake in REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in REGENXBIO in the fourth quarter valued at $54,000. Dynamic Technology Lab Private Ltd bought a new stake in REGENXBIO in the fourth quarter valued at $79,000. Teacher Retirement System of Texas increased its stake in REGENXBIO by 19.9% in the fourth quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 2,088 shares in the last quarter. Finally, EntryPoint Capital LLC bought a new stake in REGENXBIO in the fourth quarter valued at $97,000. Institutional investors own 88.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Morgan Stanley lifted their price target on shares of REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, March 14th. Chardan Capital reiterated a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a report on Thursday, March 20th. The Goldman Sachs Group decreased their target price on shares of REGENXBIO from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, April 17th. Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research report on Tuesday, March 18th. Finally, HC Wainwright decreased their target price on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Monday, March 17th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.63.

REGENXBIO Stock Performance

NASDAQ:RGNX opened at $7.97 on Tuesday. The firm has a market cap of $399.43 million, a price-to-earnings ratio of -1.58 and a beta of 1.11. REGENXBIO Inc. has a 52 week low of $5.04 and a 52 week high of $16.85. The firm has a 50-day moving average price of $7.36 and a two-hundred day moving average price of $7.99.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Wednesday, May 14th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.23). REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. As a group, sell-side analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.